Mirum Pharmaceuticals (MIRM) Competitors

Blueprint Medicines (NASDAQ:BPMC) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability, institutional ownership and community ranking.

Do analysts rate BPMC or MIRM?

Blueprint Medicines presently has a consensus price target of $129.35, indicating a potential upside of 0.93%. Mirum Pharmaceuticals has a consensus price target of $60.73, indicating a potential upside of 25.95%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Blueprint Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blueprint Medicines	0 Sell rating(s)	16 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.32
Mirum Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.17

Is BPMC or MIRM more profitable?

Blueprint Medicines has a net margin of -13.19% compared to Mirum Pharmaceuticals' net margin of -31.69%. Mirum Pharmaceuticals' return on equity of -41.22% beat Blueprint Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Blueprint Medicines	-13.19%	-77.49%	-20.84%
Mirum Pharmaceuticals	-31.69%	-41.22%	-14.81%

Does the MarketBeat Community favor BPMC or MIRM?

Blueprint Medicines received 418 more outperform votes than Mirum Pharmaceuticals when rated by MarketBeat users. However, 76.40% of users gave Mirum Pharmaceuticals an outperform vote while only 66.99% of users gave Blueprint Medicines an outperform vote.

Company	Underperform	Outperform
Blueprint Medicines	Outperform Votes 554 66.99%	Underperform Votes 273 33.01%
Mirum Pharmaceuticals	Outperform Votes 136 76.40%	Underperform Votes 42 23.60%

Which has better earnings & valuation, BPMC or MIRM?

Blueprint Medicines has higher revenue and earnings than Mirum Pharmaceuticals. Blueprint Medicines is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blueprint Medicines	$562.12M	14.72	-$67.09M	-$2.47	-51.89
Mirum Pharmaceuticals	$379.25M	6.30	-$163.41M	-$1.61	-29.95

Does the media refer more to BPMC or MIRM?

In the previous week, Blueprint Medicines had 15 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 23 mentions for Blueprint Medicines and 8 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.78 beat Blueprint Medicines' score of 0.41 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Blueprint Medicines	7 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mirum Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, BPMC or MIRM?

Blueprint Medicines has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.

Summary

Mirum Pharmaceuticals beats Blueprint Medicines on 11 of the 17 factors compared between the two stocks.